SEATTLE (AP) — On the eve of trial, Johnson & Johnson has agreed to pay $9.9 million to settle a lawsuit brought by Washington state accusing it of misrepresenting the risks of pelvic mesh...
Lower sales overseas and higher costs for research and litigation pushed Johnson & Johnson's first-quarter profit down 14%, but the health care giant beat profit and revenue expectations, pushing...
Johnson & Johnson, the world's biggest maker of health care products, wants to prevent people from getting sick — or at least stop diseases before they cause harm.
TRENTON, N.J. (AP) — Johnson & Johnson said Thursday it will start giving the list price of its prescription drugs in television ads.
The company would be the first drugmaker to take that step.
A big jump in prescription drug sales, particularly overseas, helped Johnson & Johnson swing to a large fourth-quarter profit after posting a huge loss a year earlier, when it took a $13.6 billion charge related to the late-2017 U.S. tax overhaul.
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
Adobe Inc., down $18.08 to $230
The software company gave a disappointing profit forecast for the current fiscal year.
Alaska Air Group Inc., up 96 cents to $62.30
The airline said it flew more passengers and revenue improved in November.
Sealed Air Corp., up $1.54 to $33.94
The industrial gas company announced a new restructuring program, including job cuts, aiming to save about $200 million a year.
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday:
Netflix Inc., down $21 to $379.48
The streaming video company's second-quarter subscriber gains were weaker than analysts expected.
Johnson & Johnson, up $4.42 to $129.11
The health care products company reported better results for its prescription drug business.
Hess Corp., down 42 cents to $63.46
The stocks of energy companies fell along with oil prices on Tuesday.
Fueled by a 20 percent sales jump in its prescription drugs business, Johnson & Johnson posted a 3 percent increase in second-quarter profit.
Still, the world's biggest maker of health care products trimmed its forecast for 2018.
J&J's prescription medicine business, which had lagged its medical device business until a couple years ago, accounted for half its $20.83 billion in total revenue.
BOSTON (AP) — Boston University is pairing with Johnson & Johnson to help fight lung cancer.
School officials announced Wednesday the company will pay for a new lung center at the university where researchers will work to prevent and cure the disease.
It's part of a five-year research partnership between the school and Johnson & Johnson Innovation, a development arm of the New Jersey-based health care products company.
LOS ANGELES (AP) — A California jury delivered a $25.7 million verdict against Johnson & Johnson in a lawsuit brought by a woman who claimed she developed cancer by using the company's talc-based baby powder.
Jurors in Los Angeles recommended $4 million in punitive damages Thursday after finding the company acted with malice, oppression or fraud.
Much-higher spending and one-time charges offset a12.6 percent jump in health care giant Johnson & Johnson's first-quarter revenue, trimming its profit by 1.2 percent, but the results still beat Wall Street expectations.
The maker of baby products, medical devices and blockbuster immune disorder drug Remicade on Tuesday reported revenue of $20.01 billion, topping analyst projections for $19.48 billion. Sales across J&J's three business segments all posted healthy gains.
Johnson & Johnson posted a rare quarterly loss, a whopping $10.71 billion, due to a $13.6 billion charge related to last month's U.S. tax overhaul.
While the loss was expected and the company's adjusted results beat Wall Street expectations, shares fell more than 4 percent, an unusually big swing for the health care giant.
LOS ANGELES (AP) — A judge on Friday tossed out a $417 million jury award to a woman who claimed she developed ovarian cancer by using Johnson & Johnson talc-based baby powder for feminine hygiene.
Los Angeles County Superior Court Judge Maren Nelson granted the company's request for a new trial, saying there were errors and jury misconduct in the previous trial that ended with the award two months ago.
Higher spending across the board drove Johnson & Johnson's third-quarter profit down 12 percent, despite a big sales jump fueled by recent acquisitions, hot new cancer drugs and strong sales of other key medicines.
However, the health care giant easily topped Wall Street expectations. With momentum in product sales across all three business segments, the Band-Aid maker boosted its financial forecast for the third time this year.
With a number of acquisitions and new product approvals, Johnson & Johnson looked beyond a dip in second-quarter profit and raised its outlook for the year.
The health care products giant expects sales and profit growth to accelerate this year, with momentum carrying over into 2018. The company, however, expects continued pressure to hold down prices and a weaker market for consumer health products.
TRENTON, N.J. (AP) — U.S. regulators approved a new psoriasis drug from Johnson & Johnson Thursday, giving people with the itchy and painful condition another treatment option.
Johnson & Johnson said that in one patient study, about seven in 10 patients getting the drug, Tremfya, had clear or nearly clear skin after 24 weeks of treatment. That compares with about four in 10 patients receiving rival AbbVie's Humira, which treats several immune disorders and is the world's top selling drug.
CHICAGO (AP) — Illinois will receive just over $1 million of a $33 million multi-state settlement with Johnson & Johnson to resolve allegations the health care giant sold numerous nonprescription medicines that didn't meet federal quality requirements.
FRANKFORT, Ky. (AP) — Kentucky will receive more than a half-million dollars in a settlement with a Johnson & Johnson subsidiary over nonprescription drugs.
Attorney General Andy Beshear's office said Kentucky was among 42 states and the District of Columbia involved in the lawsuit. The settlement requires Johnson & Johnson to pay a total of $33 million to be divided among the states and the district.
PORTLAND, Ore. (AP) — Johnson & Johnson has agreed to pay Oregon more than $400,000 to settle a lawsuit over a nearly decade-old buyback of defective Motrin pills.
The company discovered in 2008 that supplies of the painkiller manufactured in Puerto Rico failed to dissolve properly, which could lessen their effectiveness.
NEW YORK (AP) — U.S. stocks fell Tuesday after weak first-quarter reports from Johnson & Johnson and Goldman Sachs frustrated investors who hope that company earnings are on the rise. Health care companies lost the most.
Increased pressure to cut medicine prices and an industry-wide slowdown in consumer health product sales is hurting health care giant Johnson & Johnson.
Those factors, along with a bigger tax bill than a year ago, trimmed J&J's first-quarter profit slightly, but it still gave a rosier financial forecast for the year.
ST. LOUIS (AP) — A St. Louis jury on Friday rejected a Tennessee woman's lawsuit that Johnson & Johnson baby powder contributed to her ovarian cancer, a victory for the company after it lost three previous, similar lawsuits in St. Louis.
Johnson & Johnson edged above fourth-quarter profit expectations, helped by consumer goods and pharmaceutical growth, but the world's biggest health care products company also gave Wall Street a softer-than-expected 2017 earnings forecast.
The maker of Band-Aids and prescription drugs also said Tuesday it was taking another step in restructuring its medical device segment by shopping its diabetes care businesses, which make test strips and insulin pumps, among other products.
In a story Jan. 10 about Johnson & Johnson's plans to disclose some information on its prescription drug price increases, The Associated Press reported erroneously the use of the company's drug Xarelto. It is used to prevent strokes, not heart attacks.
A corrected version of the story is below:
Johnson & Johnson to reveal average drug price increases
PROVIDENCE, R.I. (AP) — Health care company Johnson & Johnson is opening a new health technology center in Rhode Island, bringing about 75 jobs to the state.
Democratic Gov. Gina Raimondo announced the plans Monday.
The New Brunswick, New Jersey-based company develops drugs and makes medical devices and other consumer products, including Band-Aids.
Johnson & Johnson said Tuesday it has ending talks to buy Swiss drugmaker Actelion Pharmaceuticals.
The New Brunswick, New Jersey-based health care giant said it was unable to reach a deal that would have created "adequate value" for its shareholders. Last month, it said the two were in early-stage talks about a possible deal.
NEW YORK (AP) — Johnson & Johnson said Friday that is in early talks to buy the Swiss drugmaker Actelion Pharmaceuticals.
Actelion Pharmaceuticals Ltd. makes high blood pressure medicines that treat arteries in the lung and around the heart. Johnson & Johnson of New Brunswick, New Jersey, develops drugs and manufactures medical devices and other consumer products.
Shares of Johnson & Johnson rose $1.06 to $114.13 Friday.
Johnson & Johnson shares dropped Tuesday, despite the health care bellwether boosting its third-quarter profit 27 percent. Investors apparently are worried about unexpectedly early competition to the company's longtime top seller.
NEW YORK (AP) — Johnson & Johnson said Friday that it is paying more than $4.3 billion in cash to buy the eye health unit of Abbott Laboratories as it seeks to boost its vision business.
The unit, called Abbott Medical Optics, makes lasers and other equipment used for cataract surgeries and laser vision correction procedures. It also makes eye drops and cleaners for contact lenses. AMO posted sales of $1.1 billion last year.
FRANKFORT, Ky. (AP) — The Kentucky Attorney General announced Tuesday that he's seeking thousands of dollars in damages for each patient in the state who got a vaginal mesh implant made by Johnson and Johnson and its medical device unit, accusing the companies of conducting a deceptive marketing campaign.
Surging second-quarter sales of Johnson & Johnson's prescription drugs, its healthiest business, were more than offset by a one-time gain a year ago, driving profit down 11.5 percent.
But the health care giant easily beat Wall Street's expectations and raised its full-year financial forecasts. Its shares rose to an all-time high Tuesday.
Sales of several key new medicines buoyed revenue, and medical device sales edged up. But sales dipped for consumer products...